Open Access<p>Efficacy of Combination Therapy with Linalool and Doxorubicin Encapsulated by Liposomes as a Two-in-One Hybrid Carrier System for Epithelial Ovarian Carcinoma</p>
Author(s) -
Tae In Wi,
Ji Won,
Chan Mi Lee,
JeongWon Lee,
Tae Heung Kang,
Byung Cheol Shin,
Hee Dong Han,
YeongMin Park
Publication year - 2020
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s272319
Subject(s) - liposome , doxorubicin , pharmacology , apoptosis , viability assay , ovarian carcinoma , medicine , chemotherapy , cancer research , chemistry , ovarian cancer , cancer , biochemistry
Epithelial ovarian cancer (EOC) is a fatal gynecologic malignancy that is usually treated with chemotherapy after surgery. However, patients who receive chemotherapy experience severe side effects because of the inherent toxicity and high dose of chemotherapeutics. To overcome these issues, we suggest a combination therapeutic strategy using liposomes encapsulating linalool nanoemulsions (LN-NEs) and doxorubicin (DOX), a chemotherapeutic drug, to increase their synergistic antitumor efficacy and reduce the incidence of side effects from chemotherapeutics for EOC.